Literature DB >> 10235217

Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum.

X Fan1, H Solomon, J E Poulos, B A Neuschwander-Tetri, A M Di Bisceglie.   

Abstract

OBJECTIVE: Hepatitis C virus (HCV) is known to be heterogeneous and to circulate as a group of closely related quasispecies in individual patients, although hepatic viral genetic characteristics have not been well documented.
METHODS: Matched serum and liver samples were tested by reverse transcription polymerase chain reaction amplification and single stranded conformation polymorphism analysis of the hypervariable portion of the E2/NS1 region of the HCV genome. The number of quasispecies was compared with the amount of HCV RNA, HCV genotyping, and infection with the hepatitis G virus.
RESULTS: Sixteen of 40 patients had HCV RNA detectable in serum and liver. The HCV genotype was identical in serum and liver of all but one case. HCV RNA levels were approximately 10-fold higher in liver than serum. The number of HCV quasispecies in serum ranged between two and six (median 3.0) and in the liver between 2 and 19 (median 3.5, mean liver/serum ratio 1 to 6.3, median 1.8). The number of quasispecies in liver was equal to or greater than that in serum in all cases. HGV infection was found in 14 cases and did not influence serum or hepatic levels of HCV RNA.
CONCLUSIONS: The number of hepatic HCV quasispecies usually exceeds that in serum, independent of the amount of HCV RNA and HCV genotype. This finding is compatible with clearance of some quasispecies from serum, but not liver, by putative neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235217     DOI: 10.1111/j.1572-0241.1999.01085.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

1.  Longitudinal evaluation of the structure of replicating and circulating hepatitis C virus quasispecies in nonprogressive chronic hepatitis C patients.

Authors:  B Cabot; M Martell; J I Esteban; M Piron; T Otero; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver.

Authors:  B Cabot; M Martell; J I Esteban; S Sauleda; T Otero; R Esteban; J Guàrdia; J Gómez
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.

Authors:  Keith Meyer; Arnab Basu; Craig T Przysiecki; L Martin Lagging; Adrian M Di Bisceglie; Anthony J Conley; Ranjit Ray
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.

Authors:  Xiaofeng Fan; Qing Mao; Donghui Zhou; Yang Lu; Jianwei Xing; Yanjuan Xu; Stuart C Ray; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

5.  Dynamics of hepatitis C virus replication in human liver.

Authors:  Ming Chang; Ocean Williams; John Mittler; Adrian Quintanilla; Robert L Carithers; James Perkins; Lawrence Corey; David R Gretch
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

6.  Hepatitis C virus genotype testing in paraffin wax embedded liver biopsies for specimen identification.

Authors:  Y Ikura; M Ohsawa; E Hai; H Jomura; M Ueda
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

7.  High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.

Authors:  Ditte L Hedegaard; Damien C Tully; Ian A Rowe; Gary M Reynolds; David J Bean; Ke Hu; Christopher Davis; Annika Wilhelm; Colin B Ogilvie; Karen A Power; Alexander W Tarr; Deirdre Kelly; Todd M Allen; Peter Balfe; Jane A McKeating
Journal:  J Hepatol       Date:  2016-08-13       Impact factor: 25.083

8.  Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.

Authors:  Thomas J Chambers; Xiaofeng Fan; Deborah A Droll; Edgardo Hembrador; Tiffany Slater; Michael W Nickells; Lynn B Dustin; Adrian M Dibisceglie
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

9.  Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a.

Authors:  Zekuan Xu; Xiaofeng Fan; Yanjuan Xu; Adrian M Di Bisceglie
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy.

Authors:  Peng Peng; Yanjuan Xu; Michael W Fried; Adrian M Di Bisceglie; Xiaofeng Fan
Journal:  BMC Infect Dis       Date:  2020-08-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.